The FDA approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.
Quotient Sciences acquires U.K CDMO Pharmaterials
Purdue Pharma invests in oncology R&D
NCPA statement on nomination of Alex Azar to be HHS Secretary
Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform
Marken launches app for clinical patients
The Pulse on Technology by Elisa Cascade
To set the stage for a column on paperless clinical trials, I’d like to relay a recent conversation with a PI in the U.K. working on a trial sponsored by a major pharmaceutical company.
Awards & Advancement
Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer